Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
PCOS has a wide range of negative impacts on women’s health and is one of the most frequent reproductive systemic endocrine disorders. PCOS has complex characteristics and symptom heterogeneity due to the several pathways that are involved in the infection and the absence of a comm14on cause. A recent study has shown that the main etiology and endocrine aspects of PCOS are the increased level of androgen, which is also known as “hyperandrogenemia (HA)” and secondly the “insulin resistance (IR)”. The major underlying cause of the polycystic ovary is these two IR and HA, by initiating the disease and its severity or duration. As a consequence, study on Pathogenesis is crucial to understand the effect of “HA” and “IR” on the pathophysiology of numerous symptoms linked to PCOS. A deep understanding of the pattern of the growth in PCOS for HA and IR can help ameliorate the condition, along with adjustments in nutrition and life, as well as the discovery of new medicinal products. However, further research is required to clarify the mutual role of IR and HA on PCOS development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 2×
“The following causes are highly related to PCOS: excessive embryonic androgen exposure, reactive oxygen species (ROSs), immunological, and endocrine abnormalities (6, 38).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132 · cited 2×
“CAG repeats AR and PDE8A polymorphisms, with FST SNP rs 3797297 in PCOS women (25, 31, 32).”
BackgroundDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 1×
“It is commonly established that the participation of IR and hyperinsulinemia in the development of PCOS is crucial for molecular mechanisms underpinning the endoscope hypersecretion feature of PCOS (35).”
BackgroundLegro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Moran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1018 · Cited by 1,020
Balen, A. H., Morley, L. C., Misso, M., Franks, S., Legro, R. S., Wijeyaratne, C. N., Stener-Victorin, E., Fauser, B. C. J. M., Norman, R. J., & Teede, H. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw025 · Cited by 705
Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Ehrmann, D. A., Liljenquist, D. R., Kasza, K., Azziz, R., Legro, R. S., & Ghazzi, M. N. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1329 · Cited by 703
Increased risk of depressive disorders in women with polycystic ovary syndrome
Hollinrake, E., Abreu, A., Maifeld, M., Van Voorhis, B. J., & Dokras, A. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.039 · Cited by 631
Day, F., Karaderi, T., Jones, M. R., Meun, C., He, C., Drong, A., Kraft, P., Lin, N., Huang, H., Broer, L., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007813 · Cited by 619 · cited 1×
“Pancreatic -cell dysfunction is another risk associated with PCOS and type 2 diabetes (49).”
BackgroundChang, A. M., & Halter, J. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00366.2002 · Cited by 585 · cited 1×
“It has been clear over the last two decades that both IR and -cell dysfunction is necessary for the development of diabetes mellitus, and that both of these illnesses are associated with ageing (109, 115).”
BackgroundMoran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530
Ibáñez, L., Oberfield, S. E., Witchel, S., Auchus, R. J., Chang, R. J., Codner, E., Dabadghao, P., Darendeliler, F., Elbarbary, N. S., Gambineri, A., et al. (2017) · Hormone Research in Paediatrics · doi:10.1159/000479371 · Cited by 463 · cited 1×
“Reproductive abnormalities that present as infertility (75 percent of anovulatory infertility is PCOS) and an increased risk of abortion (105, 106) are the most important concern in PCOS patients with childbearing age.”
BackgroundMechanisms of the Age-Associated Deterioration in Glucose Tolerance
Basu, R., Breda, E., Oberg, A. L., Powell, C. C., Dalla Man, C., Basu, A., Vittone, J. L., Klee, G. G., Arora, P., Jensen, M. D., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1738 · Cited by 440 · cited 2×
“Both sexes have a continuous increase in body weight with the advancement of age, which is associated with a detrimental effect on metabolic profile, and IR has long been considered the primary pathophysiological link between obesity and metabolic abnormalities (108, 109).”
BackgroundScreening for Abnormal Glucose Tolerance in Adolescents with Polycystic Ovary Syndrome
Palmert, M. R., Gordon, C. M., Kartashov, A. I., Legro, R. S., Emans, S. J., & Dunaif, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8305 · Cited by 354 · cited 1×
“According to study, women with PCOS had a higher level of intrinsic IR than their age- and BMI-matched contemporaries (112, 113).”
BackgroundHyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome
Wang, J., Wu, D., Guo, H., & Li, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116940 · Cited by 322
Age, Obesity, and Sex Effects on Insulin Sensitivity and Skeletal Muscle Mitochondrial Function
Karakelides, H., Irving, B. A., Short, K. R., O'Brien, P., & Nair, K. S. (2010) · Diabetes · doi:10.2337/db09-0591 · Cited by 293 · cited 1×
“Both sexes have a continuous increase in body weight with the advancement of age, which is associated with a detrimental effect on metabolic profile, and IR has long been considered the primary pathophysiological link between obesity and metabolic abnormalities (108, 109).”
BackgroundCorbould, A., Kim, Y.-B., Youngren, J. F., Pender, C., Kahn, B. B., Lee, A., & Dunaif, A. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00361.2004 · Cited by 283 · cited 1×
“Some PCOS women have a greater phosphorylation-172-1 receptor substratum, which inhibits insulin receptor signal (77).”
BackgroundEndoh, A., Kristiansen, S. B., Casson, P. R., Buster, J. E., & Hornsby, P. J. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.10.8855801 · Cited by 219 · cited 3×
“Additionally, adrenal reticular cells synthesize DHEA from Pregnenolone, which is derived from adrenocorticotrophic hormone (ACTH) stimulation, due to the poor expression of type II 3- hydroxysteroid dehydrogenase (HSD2) (90).”
BackgroundInfluentialNeuroendocrine dysfunction in polycystic ovary syndrome
Burt Solorzano, C. M., Beller, J. P., Abshire, M. Y., Collins, J. S., McCartney, C. R., & Marshall, J. C. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.007 · Cited by 173 · cited 1×
“On the other hand, hyperandrogenemia lowers the sensitivity to estradiol and progesterone of gonadotropic hypothalamic cells, reinforcing the GnRH and LH hypersecretion (14).”
BackgroundIs foetal hyperexposure to androgens a cause of PCOS?
Filippou, P., & Homburg, R. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx013 · Cited by 152
Hyperandrogenic origins of polycystic ovary syndrome-Implications for Pathophysiology and Therapy
Abbott, D. H., Dumesic, D. A., & Levine, J. E. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1576522 · Cited by 131 · cited 1×
“Hyperandrogenic PCOS (65) causes include PCOS ovarium (66) were discovered to be related to the hypo androgenic nature of the local ovarian immune system PCOS ovaries, but considerable alterations are possible in reactive oxygen, cytokines, and chemical species (67).”
BackgroundYang, R., Yang, S., Li, R., Liu, P., Qiao, J., & Zhang, Y. (2016) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-016-0203-8 · Cited by 106 · cited 1×
“Vitamin D encourages the formation of adipose cells, influences lipid and metabolic enzymes by carbohydrate activation, and stimulates tissue breakdown in the adipose (78).”
BackgroundKasim-Karakas, S. E., Almario, R. U., Gregory, L., Wong, R., Todd, H., & Lasley, B. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030666 · Cited by 99
Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome
Sam, S., & Ehrmann, D. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4306-3 · Cited by 93
Fux Otta, C., Wior, M., Iraci, G. S., Kaplan, R., Torres, D., Gaido, M. I., & Wyse, E. P. (2010) · Gynecological Endocrinology · doi:10.3109/09513590903215581 · Cited by 85
Yilmaz, M., Biri, A., Karakoç, A., Törüner, F., Bingöl, B., Çakir, N., Tiras, B., Ayvaz, G., & Arslan, M. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03345339 · Cited by 77
Aroda, V. R., Ciaraldi, T. P., Burke, P., Mudaliar, S., Clopton, P., Phillips, S., Chang, R. J., & Henry, R. R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1133 · Cited by 71
Prenatal Exposure to Endocrine Disruptors: A Developmental Etiology for Polycystic Ovary Syndrome
Hewlett, M., Chow, E., Aschengrau, A., & Mahalingaiah, S. (2017) · Reproductive Sciences · doi:10.1177/1933719116654992 · Cited by 61
Abnormal infant islet morphology precedes insulin resistance in PCOS-like monkeys
Nicol, L. E., O’Brien, T. D., Dumesic, D. A., Grogan, T., Tarantal, A. F., & Abbott, D. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106527 · Cited by 41 · cited 1×
“Furthermore, the babies showed that the proliferative marker Ki67 was elevated and the cell/+ cell ratio of the islets was increasing (79).”
BackgroundTao, T., Wu, P., Wang, Y., & Liu, W. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0243-5 · Cited by 38 · cited 1×
“The fact that metformin promotes insulin secretion, especially in the early stages of secretion, is unacceptable without the traditional symptoms of PCOS (94).”
Background
Cited by
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041454 · Cited by 521
The interplay between androgens and the immune response in polycystic ovary syndrome
Shabbir, S., Khurram, E., Moorthi, V. S., Eissa, Y. T. H., Kamal, M. A., & Butler, A. E. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04116-4 · Cited by 108
Mei, S., Ding, J., Wang, K., Ni, Z., & Yu, J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.876620 · Cited by 75
Zhou, J., Zuo, W., Tan, Y., Wang, X., Zhu, M., & Zhang, H. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01130-4 · Cited by 16
Metadata
- Authors
- Ding, H., Zhang, J., Zhang, F., Zhang, S., Chen, X., Liang, W., & Xie, Q.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2021-10-20
- Volume
- 12
- Pages
- 741764-741764
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3207324705
- Cited by
- 228
- References
- 32
- FWCI
- 17.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.